GeneDx Holdings Corp. reports developments in genomic testing for rare disease diagnosis, with recurring updates on ExomeDx™ and GenomeDx™ testing, exome and genome test volumes, revenue growth, and full-year outlooks. The company uses GeneDx Infinity™, a rare disease genomic dataset, to support clinical interpretation, AI-enabled variant analysis, and biopharma discovery.
Company news also covers research publications and medical-meeting abstracts, health economics studies involving whole exome and whole genome sequencing, sponsored genetic testing programs for suspected rare diseases, and partnerships intended to expand access to genomic diagnosis. Updates frequently connect clinical data, sequencing technology, and rare disease patient identification with the company's precision-medicine operating model.
GeneDx (WGS) will release its third-quarter 2026 financial results after the market closes on November 9, 2026. Management will discuss financial and operating results on a conference call that day at 4:30 p.m. Eastern Time. A live and archived webcast will be available in the Events section of the company’s investor relations website.
GeneDx (Nasdaq: WGS) announced plans to add long-read whole genome sequencing to its portfolio of tests for rare disease diagnosis. The technology analyzes longer stretches of DNA to identify complex genetic changes, including certain structural variants and repeat expansions that traditional short-read sequencing can miss.
GeneDx plans to use its Infinity genomic dataset and clinical interpretation expertise to identify patients most likely to benefit and offer the test upfront to eligible patients. This approach uses patients' observable clinical characteristics to guide testing. The company aims to reduce sequential testing, close diagnostic gaps and accelerate diagnosis. The early access program is expected to be available by year-end 2026.
GeneDx (Nasdaq: WGS) plans to expand its genome testing portfolio with long-read whole genome sequencing for rare disease diagnosis. The company expects an early access program by year-end 2026. Long-read sequencing examines longer stretches of DNA to identify complex genetic changes, including certain structural variants and repeat expansions that traditional short-read sequencing can miss.
GeneDx plans to use GeneDx Infinity data and clinical interpretation to identify patients who could benefit most, offering the test upfront to eligible patients. Its approach will consider patients’ clinical characteristics alongside genomic information. The company aims to reduce sequential testing, address diagnostic gaps and accelerate diagnosis; these are intended benefits rather than reported results from the planned program.
GeneDx (Nasdaq: WGS) announced 27 accepted scientific abstracts covering genomic testing research at the American Society of Human Genetics 2026 Annual Meeting. The program includes three platform presentations, three rapid-fire poster talks and a Reviewer’s Choice poster, an honor awarded to the top 10% of posters.
Research topics include machine learning to prioritize copy number variants, or changes in the number of copies of DNA segments, and factors influencing diagnostic yield in more than 100,000 individuals with autism. GUARDIAN research examines genomic newborn screening findings across diverse genetic ancestries in more than 19,000 newborns. Nine abstracts address gene discovery using GeneDx Infinity, GeneMatcher and global collaborations. All study results remain under embargo until their respective presentations or poster sessions.
GeneDx (WGS) announced genomic newborn screening findings for presentation at ICoNS in Boston on October 7–8, including GUARDIAN study results.
GUARDIAN has enrolled 30,000 newborns; 72.3% of families approached participated, and 76% of participating newborns have non-European genetic ancestry. Excluding glucose-6-phosphate dehydrogenase deficiency, screen-positive rates were relatively consistent across ancestries. Genomic screening found conditions missed by standard screening, while standard screening found select cases missed by genomic screening. Long QT syndrome findings led to preventive treatment for infants and relatives.
BRIDGES-NBS, an NIH-funded program collaborating with GeneDx, plans to begin enrollment in October with 746 genes covering 777 genetic conditions treatable in the first year of life, and expand across eight states and territories.
GeneDx (WGS) will introduce Easy Order at the 2026 American Academy of Pediatrics conference to simplify genomic test ordering for pediatricians. The conference runs October 2–6 in San Diego. Available through the GeneDx Provider Portal, the guided workflow reduces required inputs for ordering ExomeDx and chromosomal microarray, a test for chromosome changes.
GeneDx is also developing Provider Report Guides with explanations intended to help clinicians understand and communicate genetic results. It serves as the implementation partner for the LEAD Project, a national initiative advancing earlier genomic testing for children with developmental delay and related conditions.
GeneDx (WGS) announced a collaboration with Beren Therapeutics to launch NPC GenomeComplete, a sponsored genetic testing program for suspected Niemann-Pick Disease Type C (NPC) in children. The initiative offers no-cost comprehensive genome sequencing, NPC1/NPC2 variant testing, and expert diagnostic support for eligible pediatric patients with clinical signs, family history, or biomarker evidence of NPC. Rapid genome sequencing is available for urgent cases, with preliminary results in as soon as 48 hours. Beren fully sponsors testing, which does not require insurance, aiming to reduce diagnostic barriers and identify undiagnosed children with this rare, progressive neurodegenerative disorder.
GeneDx (Nasdaq: WGS) announced that CEO Katherine Stueland has been named a 2026 Fierce 50 honoree for Health Equity by Fierce Pharma, Fierce Biotech and Fierce Healthcare. The Fierce 50 highlights 50 individuals and organizations advancing medicine, innovation and the future of biopharma and healthcare.
According to GeneDx, the recognition underscores its role in moving genomic medicine into routine care through deep clinical expertise, advanced technology and GeneDx Infinity™, described as the world’s largest rare disease genomic dataset powering its ExomeDx™ and GenomeDx® tests and biopharma discovery.
GeneDx (Nasdaq: WGS) announced publication of a large study in Genetics in Medicine with Seattle Children’s showing that hospital-wide, first-tier rapid genome sequencing (rGS) for more than 1,000 pediatric inpatients over 3.5 years improved diagnostic rates and access to genomic testing.
According to GeneDx, rGS achieved a 35% overall diagnostic yield, including 43% in non-ICU wards and a striking 63% among children evaluated for faltering growth, identifying 37 distinct genetic diagnoses. The model reportedly reduced outpatient genetics wait times and eliminated race-based disparities in access to testing.
GeneDx (Nasdaq: WGS) launched a new online offering to expand access to clinician-guided exome testing for U.S. pediatric patients with global developmental delay (GDD), intellectual disability (ID) or epilepsy. Families can now initiate testing directly via GeneDx.com, where licensed clinicians review medical information, order tests and deliver results virtually.
According to GeneDx, this is designed for eligible children who face long waits or limited access to genetics specialists, complementing existing care from pediatricians, neurologists or other providers. The service is available nationwide, subject to provider availability, clinical appropriateness and state requirements, and aims to enable earlier, more precise diagnoses in line with updated American Academy of Pediatrics guidance.